Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.

Abstract

PURPOSE:

Dexrazoxane administration prior to short infusion doxorubicin prevents anthracycline-related heart damage. Since delivery of doxorubicin by 96-h continuous intravenous infusion also reduces cardiac injury, we studied delivering dexrazoxane and doxorubicin concomitantly by prolonged intravenous infusion.

METHODS:

Patients with advanced malignancies received tandem cycles of concurrent 96-h infusions of dexrazoxane 500 mg/m2 and doxorubicin 165 mg/m2, and 24 h after completion of chemotherapy, granulocyte-colony stimulating factor (5 microg/kg) and oral levofloxacin (500 mg) were administered daily until the white blood cell count reached 10,000 microl(-1). Plasma samples were analyzed for dexrazoxane and doxorubicin concentrations.

RESULTS:

Ten patients were enrolled; eight patients had measurable disease. Two partial responses were observed in patients with soft-tissue sarcoma. The median number of days of granulocytopenia (<500 microl(-1)) was nine and of platelet count <20,000 microl(-1) was seven. Six patients received a single cycle because of progression (one), stable disease (four), or reversible, asymptomatic 10% decrease in cardiac ejection fraction (two). Principal grade 3/4 toxicities included hypotension (two), anorexia (four), stomatitis (four), typhlitis (two), and febrile neutropenia (seven), with documented infection (three). One death from neutropenic sepsis occurred. Dexrazoxane levels ranged from 1270 to 2800 nM, and doxorubicin levels ranged from 59.1 to 106.9 nM.

CONCLUSIONS:

These results suggest that tandem cycles of concurrent 96-h infusions of dexrazoxane and high-dose doxorubicin can be administered with minimal cardiac toxicity, and have activity in patients with recurrent sarcomas. However, significant non-cardiac toxicities indicate that the cardiac sparing potential of this approach would be maximized at lower dose levels of doxorubicin.

• Authors: Warren A Chow, Timothy W Synold, Merry L Tetef, Jeffrey Longmate, Paul Frankel, Joyce Lawrence, Zaid Al-Khadimi, Lucille Leong, Dean Lim, Kim Margolin, Robert J Morgan Jr, James Raschko, Stephen Shibata, George Somlo, Przemyslaw Twardowski, Yun Yen, James H Doroshow
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 54 Issue 3 Pg. 241-8 (Sep 2004) ISSN: 0344-5704 [Print] Germany
• PMID: 15173955 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antibiotics, Antineoplastic
• Cardiovascular Agents
• Granulocyte Colony-Stimulating Factor
• Razoxane
• Levofloxacin
• Doxorubicin
• Ofloxacin

Topics

• Adult
• Antibiotics, Antineoplastic (administration & dosage, adverse effects)
• Cardiovascular Agents (administration & dosage, pharmacokinetics)
• Doxorubicin (administration & dosage, adverse effects)
• Drug Administration Schedule
• Drug Therapy, Combination
• Female
• Granulocyte Colony-Stimulating Factor (administration & dosage)
• Heart Failure (chemically induced, prevention & control)
• Humans
• Infusions, Intravenous
• Levofloxacin
• Male
• Middle Aged
• Neoplasms (drug therapy)
• Neutropenia (chemically induced)
• Ofloxacin (administration & dosage)
• Razoxane (administration & dosage, pharmacokinetics)
• Sarcoma (drug therapy)
• Sepsis
• Treatment Outcome